Mike Grey currently serves as Chairman of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Sorriso Pharmaceuticals, Inc. and as Executive Chair of Plexium, Inc., Spruce Biosciences, Inc. (NASDAQ: SPRB) and Theolytics Ltd. He is also a venture partner at Pappas Capital.
Mike is a founder of Reneo Pharmaceuticals, Inc. and has served in the roles Executive Chairman, Chairman, and Chief Executive Officer. Additionally, Mike was previously Executive Chairman and Chief Executive Officer of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), Chief Executive Officer and Executive Chairman of Amplyx Pharmaceuticals, Inc. (acquired by Pfizer), Executive Chairman of Curzion Pharmaceuticals, Inc. (acquired by Horizon) and President and Chief Executive Officer of Lumena Pharmaceuticals, Inc. (acquired by Shire).
Mike previously served on the board of directors of a number of public companies, including BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN), Horizon Therapeutics plc (NASDAQ: HZNP), and Mirati Therapeutics, Inc.
Mike has more than 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including President and Chief Executive Officer of SGX Pharmaceuticals, Inc. (acquired by Lilly), President and Chief Executive Officer of Trega Biosciences, Inc. (acquired by LION Bioscience) and President of BioChem Therapeutic Inc. Prior to these, Mike served in various roles with Glaxo, Inc., and Glaxo Holdings PLC, culminating in his position as Vice President, Corporate Development and Director of International Licensing. Mr. Grey received a B.Sc. in chemistry from the University of Nottingham in the United Kingdom.